Abstract
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
Publication types
-
Clinical Trial, Phase I
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Brentuximab Vedotin
-
Dacarbazine / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Drug Interactions
-
Female
-
Follow-Up Studies
-
Hodgkin Disease / drug therapy*
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / adverse effects
-
Immunoconjugates / pharmacology
-
Kaplan-Meier Estimate
-
Lung Diseases / chemically induced
-
Male
-
Middle Aged
-
Molecular Targeted Therapy*
-
Remission Induction
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Young Adult
Substances
-
Antineoplastic Agents, Immunological
-
Immunoconjugates
-
Bleomycin
-
Vinblastine
-
Dacarbazine
-
Brentuximab Vedotin
-
Doxorubicin